Vol 7, No 1 (2021)
Review paper
Published online: 2021-05-20

open access

Page views 1547
Article views/downloads 807
Get Citation

Connect on Social Media

Connect on Social Media

Rola odpowiedzi przeciwwirusowej z udziałem interferonów w patogenezie chorób autoimmunologicznych i nowe możliwości terapeutyczne

Olga Gumkowska-Sroka1, Przemysław Jacek Kotyla2
Forum Reumatol 2021;7(1):19-26.

Abstract

Interferony to szeroka grupa cytokin biorących udział w nieswoistej odpowiedzi immunologicznej, stanowią ważny czynnik patogenetyczny odpowiedzialny za powstawanie oraz przebieg kliniczny licznych chorób autoimmunologicznych. W ostatnich latach opisano i zdefiniowano zjawisko regulacji wielu genów odpowiedzialnych za procesy zapalne i autoimmunologiczne określane wspólną nazwą sygnatury interferonu. W niniejszej pracy dokonano przeglądu znaczenia interfonów w patogenezie chorób autoimmunologicznych z uwzględnieniem terapeutycznych możliwości regulacji odpowiedzi zapalnej zależnej od interferonów

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Jiménez-Dalmaroni MJ, Gerswhin ME, Adamopoulos IE. The critical role of toll-like receptors--From microbial recognition to autoimmunity: A comprehensive review. Autoimmun Rev. 2016; 15(1): 1–8.
  2. Rönnblom L. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol. 2016; 34(4 Suppl 98): 21–24.
  3. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 2008; 89(Pt 1): 1–47.
  4. Stark G, Kerr I, Williams B, et al. How cells respond to interferons. Annual Review of Biochemistry. 1998; 67(1): 227–264.
  5. Dagenais-Lussier X, Loucif H, Murira A, et al. Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for Protective Immunity. Viruses. 2017; 10(1).
  6. Palanichamy A, Bauer JW, Yalavarthi S, et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J Immunol. 2014; 192(3): 906–918.
  7. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011; 70(11): 2029–2036.
  8. Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005; 52(4): 1185–1195.
  9. James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001; 44(5): 1122–1126, doi: 10.1002/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D.
  10. Crow MK. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr Opin Rheumatol. 2014; 26(5): 467–474.
  11. Isaksson M, Ardesjö B, Rönnblom L, et al. Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE. Eur J Immunol. 2009; 39(10): 2925–2935.
  12. Lövgren T, Eloranta ML, Båve U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004; 50(6): 1861–1872.
  13. Yasutomo K, Horiuchi T, Kagami S, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 2001; 28(4): 313–314.
  14. Markowitz J, Luedke EA, Grignol VP, et al. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother. 2014; 37(1): 55–62.
  15. Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002; 21(8): 1251–1262.
  16. Ho V, Mclean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol. 2008; 14(3): 166–168.
  17. Platanias LC, Uddin S, Domanski P, et al. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. J Biol Chem. 1996; 271(39): 23630–23633.
  18. Huard C, Gullà SV, Bennett DV, et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis. Br J Dermatol. 2017; 176(5): 1224–1230.
  19. Bissonnette R, Papp K, Maari C, et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol. 2010; 62(3): 427–436.
  20. Li M, Liu X, Zhou Y, et al. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009; 86(1): 23–32.
  21. Migliorini A, Angelotti ML, Mulay SR, et al. The antiviral cytokines IFN-α and IFN-β modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am J Pathol. 2013; 183(2): 431–440.
  22. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2009; 68(9): 1440–1446.
  23. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013; 72(5): 728–735.
  24. Hauer AC, Finn TM, MacDonald TT, et al. Analysis of TH1 and TH2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated in vitro with Helicobacter pylori. J Clin Pathol. 1997; 50(11): 957–959.
  25. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun. 2010; 35(3): 225–231.
  26. Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2012; 14(3): R155.
  27. Furie R, Khamashta M, Merrill JT, et al. CD1013 Study Investigators. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2): 376–386.
  28. Merrill JT, Wallace DJ, Petri M, et al. Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011; 70(11): 1905–1913.
  29. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012; 64(11): 3666–3676.
  30. Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63(8): 2407–2415.
  31. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum. 2013; 65(2): 447–456.